An International Congress on Lymphoma, Myeloma, and ...M/LM18-3e.pdf · In support of improving...

October 17–20, 2018 New York City

An International Congress on Lymphoma, Myeloma, and Leukemia Disorders

lymphomaandmyeloma.com

NEW DAY!New Approaches

in Acute Leukemias and Hematologic

MalignanciesWednesday, October 17

REGISTER TODAY: 800-233-0957; INTERNATIONAL: 678-242-0906

For the past 18 years, the Lymphoma & Myeloma Congress

has been recognized around the world as the most

respected forum for industry-leading hematologic research

—it’s where interdisciplinary specialists convene to explore

the controversial and the complex, the emerging and the

exciting, and discuss, debate, and discover along the way.

This year, make plans to join us for four days of

comprehensive learning as we examine new research,

discover innovative treatment methods, and analyze new

trends impacting the future of lymphoma, myeloma, and

leukemia disorders.

CONGRESS CHAIR

Morton Coleman, MD Weill Cornell Medicine New York, New York

CO-CHAIR, LYMPHOMA SESSION

John P. Leonard, MD Weill Cornell Medicine New York, New York

CO-CHAIR, MYELOMA SESSION

Ruben Niesvizky, MD Weill Cornell Medicine New York, New York

CO-CHAIR, CLL SESSION

Richard R. Furman, MD Weill Cornell Medicine New York, New York

CO-CHAIR, ACUTE LEUKEMIA & HEMATOLOGIC MALIGNANCIES SESSION

Gail J. Roboz, MD Weill Cornell Medicine New York, New York

REGISTER BY JULY 31, 2018 | LYMPHOMAANDMYELOMA.COM

ENDORSED BY

SUPPORT

The following companies are supporters of

this Congress:

GOLD

Karyopharm Therapeutics

Seattle Genetics

Several options are available

for companies interested in

supporting this Congress. For

more information, please contact

Imedex by email at [email protected].

Lymphoma & Myeloma is genuinely one of the

best meetings of the year. The detailed agenda

allows for a deep dive into these complex

diseases and provides practical advice for

the treating clinician. The time allowed for

Q&A makes this program unique, facilitating

excellent interaction with the faculty, who are

truly the leaders in the field. A mix of debates

and didactic lectures keeps the audience

engaged and encourages outstanding

education.”

Joseph Mikhael, MD Chief Medical Officer International Myeloma Foundation

“

REGISTER TODAY: 800-233-0957 | INTERNATIONAL: 678-242-0906

NEW APPROACHES IN ACUTE LEUKEMIA & HEMATOLOGIC MALIGNANCIES WEDNESDAY, OCTOBER 17, 2018

10:30 AM Welcome: Gail J. Roboz, MD

Session I: Acute Leukemias

10:40 AM Pre-Session Audience Survey

10:50 AM Diagnosis and Treatment of Newly Diagnosed ALL

11:10 AM Immunotherapy of ALL

11:30 AM DEBATE: Which Patients Should Be Transplanted for ALL?

12:00 PM Panel Discussion and Post-Session Audience Survey

12:15 PM Luncheon Programs

Session II: MPN & MDS

1:45 PM Pre-Session Audience Survey

1:55 PM Monitoring Patients on Longstanding TKI Therapy for CML: What to Look for Other Than BCR-ABL

2:15 PM Treatment Strategies for Myelofibrosis

2:35 PM MDS: Is Your Hypomethylator Working?

2:55 PM DEBATE: Which Patients with CML Should Stop TKI Therapy?

3:25 PM Panel Discussion and Post-Debate Audience Survey

3:40 PM Break

Session III: Special Topics


4:10 PM Newly Diagnosed AML: Hitting the Right Target

4:30 PM AML: What to Do with Your 500-Gene Mutation Report

4:50 PM MRD in AML: What is It and What Do I Do About It?

5:10 PM AML 60-80 Years: Who Should Get an Allo Transplant?


5:45 PM Session Adjourn

5:45 PM Exhibit Hall/Product Theater Opening

This program features 4 days of comprehensive learning as we analyze emerging data, discover innovative treatment methods, and get a glimpse into the future of lymphoma, myeloma, and leukemia disorders.

SC

IEN

TIFI

C A

GEN

DA


MYELOMA SESSION THURSDAY, OCTOBER 18, 20188:00 AM Welcome: Morton Coleman, MD 8:05 AM Introduction to Myeloma

Session: Ruben Niesvizky, MD

Session I: Precision Medicine in Myeloma


8:20 AM Genomics 101: From Deep Sequencing to Liquid Biopsies

8:40 AM Genomics 102: Clinical Use for Treatment Individualization, Including Double-Hit Myeloma

9:00 AM DEBATE: MRD: Ready for Prime Time?

Yes, Is MRD for Novel Agents the Same as for Transplantation?

No, MRD Does Inform Length of Induction, Need for Transplant/Consolidation, Maintenance

9:30 AM Panel Discussion and Post-Session Audience Survey

9:50 AM Break

Session II: Immuno-Oncology


10:20 AM Vaccination as a Therapeutic Approach in Myeloma

10:40 AM Anti CD38, SLAMF-7, and BiTE Immunotherapy: Are Immune Therapeutics Ready for the Front Line?

11:00 AM CAR-T: State of the Art and Perspective of a Possible Cure

11:20 AM DEBATE: Is Allotransplant Relevant Today in Myeloma? Yes vs. No

11:50 AM Panel Discussion and Post-Debate Audience Survey

12:10 PM Lunch

Session III: Treatment


1:50 PM Precursor Disorders in Myeloma: Can We Cure Some?

2:10 PM Management of the Fit Patient: Induction, Which One to Choose, 3 or 4 Drugs

2:30 PM Management of the Unfit and Frail Patient


3:10 PM Break

Session IV: Special Lectures

3:30 PM Best Myeloma Abstract Presentation

3:40 PM New Horizons in the Treatment of Relapsed and Refractory Myeloma

4:00 PM The SAAS Foundation for Medical Research Award: Michaeli Award for Contribution to Myeloma

4:10 PM Keynote Lecture: Is Myeloma Curable?

4:40 PM Panel Discussion

4:50 PM Adjourn


CLL SESSION FRIDAY, OCTOBER 19, 2018 8:00 AM Welcome: Morton Coleman, MD 8:05 AM Introduction to CLL Session:

Richard Furman, MD

Session V: Small Molecule Inhibitors


8:20 AM Update on BTK Inhibitors: Ibrutinib Plus the New Kids on the Block: Are They Better?

8:40 AM Update on PI3K Inhibitors: Idelalisib, Copanlisib, Duvelisib, Umbralisib: Is Toxicity the Key?

9:00 AM Update on Venetoclax: How Low Can You Go (MRD)?


9:40 AM Break

Session VI: The Future of CLL


10:10 AM Update on Chemotherapy in 2018: Is Chemotherapy Passé?

10:30 AM Treatment Options for the Young Patient with Deletion 17p: Do They Need a Different Approach?

10:50 AM Does Sequence Matter for Novel Therapies?

11:10 AM What’s Next in CLL?


11:50 AM Session Adjourn

11:50 AM Luncheon Programs

Session VII: Special Topics in CLL


1:30 PM Ethnic, Environmental, Genetic, and Familial Risk Factors for CLL

1:50 PM Prince Family Lecture: Small RNAs and Their Role in CLL: Molecular Breakthroughs?

2:10 PM Bruce Waterfall Memorial Lecture: What are the Best Front-Line Therapies for Waldenström Macroglobulinemia?

2:30 PM Bruce Waterfall Memorial Lecture: What are the Newest Therapies for Relapsed Refractory Waldenström Macroglobulinemia?

2:50 PM Post-Session Audience Survey

3:00 PM Break

Session VIII: CLL Transformation


3:30 PM Gebroe Family Lecture: Can We Predict Who Will Get Richter’s Transformation?

3:50 PM Therapeutic Options for Richter’s Syndrome

4:10 PM Where are We with CAR T-Cells in CLL? What are the Data? Does It Work for Transformation?


4:50 PM Adjourn

SC

IEN

TIFI

C A

GEN

DA


LYMPHOMA SESSION SATURDAY, OCTOBER 20, 20188:00 AM Welcome: Morton Coleman, MD 8:05 AM Introduction to Lymphoma

Session: John Leonard, MD

Session IX: Special Topics in Lymphoma


8:20 AM Patient-Derived Xenografts (PDX) in Lymphoma: How Can They Help Advance Therapy?

8:40 AM New Targets and Tools in Lymphoma Treatment

9:00 AM Vitamin D in Lymphoma Therapy: What is Its Role, and Should We Supplement?


9:40 AM Break

Session X: New Directions in Lymphoma

10:00 AM Pre-Session Survey

10:10 AM DEBATE: What is the Best Upfront Approach for the Treatment of Advanced Stage Hodgkin’s Lymphoma?

Side 1: A (Brentuximab Vedotin) VD

Side 2: A (Bleomycin) VD

10:40 AM DEBATE: Is Obinutuzumab Superior to Rituximab in Lymphoma? Yes vs. No

11:10 AM Auto-Transplant vs. CAR-T: How Should We Sequence Therapy, and Who Should Receive Therapy?


Session XI: Immunotherapy in Lymphoma

11:50 AM Presentation of Best Lymphoma Abstract

12:00 PM The SAAS Foundation for Medical Research Award Ceremony

12:10 PM Immunotherapy of Hodgkin’s and Non-Hodgkin’s Lymphoma

12:40 PM Discussion

12:45 PM Session Adjourn

12:45 PM Luncheon Programs

Session XII-A: Breakouts: Indolent and Mantle Cell Lymphoma

2:15 PM Breakout #1: New Data on Upfront and Maintenance Therapy in Follicular Lymphoma

2:35 PM Breakout #2: How I Approach Early Relapsing Follicular Lymphoma

2:55 PM Breakout #3: How I Approach the Initial Treatment of Mantle Cell Lymphoma

3:15 PM Breakout #4: Novel Agents and Approaches for Mantle Cell Lymphoma

3:35 PM Break


LYMPHOMA SESSION SATURDAY, OCTOBER 20, 2018

Session XII-B: Breakouts: Aggressive and T-Cell Lymphoma (Concurrent with XII-A)

2:15 PM Breakout #5: How Should We Treat Double-Hit and Double-Expressor DLBCL?

2:35 PM Breakout #6: New Drugs for Aggressive Lymphoma

2:55 PM Breakout #7: New Developments in Primary and Secondary CNS Lymphoma: Prevention and Treatment

3:15 PM Breakout #8: Novel Approaches for T-Cell Lymphoma

3:35 PM Break

Session XIII-A: Breakouts: Indolent and Mantle Cell Lymphoma

3:55 PM Breakout #1: New Data on Upfront and Maintenance Therapy in Follicular Lymphoma

4:15 PM Breakout #2: How I Approach Early Relapsing Follicular Lymphoma

4:35 PM Breakout #3: How I Approach the Initial Treatment of Mantle Cell Lymphoma

4:55 PM Breakout #4: Novel Agents and Approaches for Mantle Cell Lymphoma

5:15 PM Adjourn

Session XIII-B: Breakouts: Aggressive and T-Cell Lymphoma

3:55 PM Breakout #5: How Should We Treat Double-Hit and Double-Expressor DLBCL?

4:15 PM Breakout #6: New Drugs for Aggressive Lymphoma

4:35 PM Breakout #7: New Developments in Primary and Secondary CNS Lymphoma: Prevention and Treatment

4:55 PM Breakout #8: Novel Approaches for T-Cell Lymphoma

5:15 PM Adjourn

SC

IEN

TIFI

C A

GEN

DA


CONCURRENT NURSE PRACTITIONER AND PHYSICIAN ASSISTANT SESSIONS THURSDAY, OCTOBER 18, 2018

Session I: Updates in Multiple Myeloma

8:45 AM Welcome and Introduction of Track: Morton Coleman, MD

8:55 AM Track Overview: Jeremy T. Heinerich, PA-C


9:10 AM Role of Immunomodulating Agents in Multiple Myeloma

10:10 AM Break

10:25 AM Role of Transplant in Multiple Myeloma

11:25 AM Interpretation of Bone Marrow Biopsies in Hematologic Malignancies

12:25 PM Post-Session Audience Survey

12:35 PM Lunch

FRIDAY, OCTOBER 19, 2018

Session II: Updates in CLL




9:15 AM Managing Toxicities of Oral Therapies in CLL

10:15 AM Break

10:35 AM Role of MRD Negativity in CLL

11:35 AM Post-Session Audience Survey

11:45 AM Lunch

SATURDAY, OCTOBER 20, 2018

Session III: Hands-On Workshops in Lymphoma



8:30 AM Bone Marrow Biopsy Workshop

9:30 AM Lumbar Puncture Workshop

10:30 AM Break

11:00 AM CAR T-Cell in Lymphoma

12:00 PM Hodgkin’s Lymphoma Updates

1:00 PM Lunch

“The concentration of clinical treatment, prognostic, and biologic advances in

lymphoma, myeloma, and CLL, as well as how they impact current practice care,

is the key strength and takeaway.”


CONTINUING EDUCATIONPhysicians

Imedex®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This activity has been approved for AMA PRA Category 1 CreditsTM.

Maintenance of Certification

ABIM MOC Successful completion of this CME activity enables a participant to earn MOC points

towards the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is Imedex’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC Points.

Pharmacy

Imedex®, LLC is accredited by the Accredita-tion Council for Pharmacy Education as a provider of continuing pharmacy education.

Nursing

In support of improving patient care, North American Center for Continuing Medical Education (NACCME) is jointly accredited by the Accreditation Council for Continuing Medical Education

(ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Who Should Attend

This educational activity is designed for domestic and international healthcare clinicians, including hematologists and hematologic oncologists, medical, radiation, and surgical oncologists, and other healthcare professionals (physicians, physicians-in-training, oncology nurses, nurse practitioners, pharmacists, physician assistants, etc.) who are involved and/or interested in the treatment of patients with hematologic malignancies.

Learning Objectives

Upon successful completion of these educational activities, participants should be better able to:

» Interpret efficacy and safety results from recent clinical trials that led to the approval of new pharmacologic agents for the treatment of leukemias, lymphomas, or myeloma

» Assess the prognostic impact of molecular biomarkers and genetic mutations that are common to hematologic malignancies

» Evaluate the emerging role of immunotherapies as an intervention for hematologic malignancies that are known to have an immunologic component

» Devise tailored therapeutic strategies designed to realize optimal therapeutic response from hematologic cancer patients who are either fit or frail

» Describe the mechanisms of action of new or emerging treatments that are designed to target molecular biomarkers or genetic aberrations that are frequently observed in hematologic cancers

» Assess both established and recently pioneered sequencing and combination strategies for second-line or salvage therapy interventions

EXHIBITORS

Exhibit space is available for companies interested in exhibiting at this Congress. For more information, please contact Imedex at 678.242.0719 or [email protected].


Sheraton New York Times Square Hotel811 W. 7th Avenue New York, New York 10019

Congress Location and Accommodations

REGISTRATION RATES

EARLY

Through 7/31/18

DISCOUNTED

8/1/18 – 9/14/18

REGULAR/ ONSITE

9/15/18 – 10/20/18

Physician, Pharmacist, and Non-Clinician

Researcher$549 $349 $749

Physician Assistant, Nurse Practitioner $349 $399 $449

Nurse, Fellow, Resident, Student,

Trainee$199 $249 $299

Pharmaceutical Personnel $899

Reserve Your Room Online at: aws.passkey.com/go/Imedex2018

Register online at lymphomaandmyeloma.comor call800.233.0957 (US)1.678.242.0906 (INTL)

Register by July 31, 2018 to secure your place at the best rate.

Special Room Rate: $324/night plus tax

Oct

ober

17–

20

, 20

18 |

New

Yor

k, N

Y

Reg

iste

r by

Jul

y 3

1 to

res

erve

yo

ur s

eat

at t

he b

est

rate

.

lym

phom

aand

mye

lom

a.co

m

116

75 R

ainw

ater

Drive

, Sui

te 6

00

A

lpha

rett

a, G

A 3

00

09

, US

A

Date post:	03-Jul-2018
Category:	Documents
Upload:	dothu
View:	213 times
Download:	0 times

An International Congress on Lymphoma, Myeloma, and ...M/LM18-3e.pdf · In support of improving...

Documents